The overall mission of the Oncology Department is to improve cure rates for children with cancer while reducing the side effects of therapy through a coordinated program of clinical and laboratory-based research, patient care and education. We will achieve this by close collaboration between laboratory and clinical research to understand better how cancer behaves in children and young adults. We will use this knowledge to discover new and more effective therapies for childhood malignancies while minimizing the long-term effects on our patients.
Our Oncology faculty are world leaders in identifying novel drugs and treatment modalities, defining the clinical significance of recently discovered genetic abnormalities of cancer cells, understanding mechanisms of cancer development and drug resistance, and understanding and preventing late effects of therapy. We aim to share our unique clinical expertise with colleagues nationally through our many clinical trial consortia and worldwide through our partnership with St. Jude Global. The ultimate goal of our research is to ensure that every child with cancer receives curative therapy and that this therapy allows them the potential for a healthy, long-lasting life.
Dr. Julie R. Park is a pediatric hematologist-oncologist who is interested in developing and advancing new approaches to childhood cancer therapy. Dr. Park received her MD from the University of Vermont and completed residency training in pediatrics at the University of Washington. Dr. Park then completed a fellowship in pediatric hematology/oncology at the University of Washington and Fred Hutchinson Cancer Research Center.
She has been funded as a Fellow for the Leukemia Society of America at Fred Hutchinson Cancer Research Center, and an investigator on NCI and NIH grants. As a Member of the St. Jude Faculty and Chair of the Oncology Department, Dr. Park is interested in discovering the molecular and immunologic vulnerabilities of solid tumor malignancies, such as neuroblastoma, and using this information to inform clinical trials centered on novel therapies for children with relapsed or refractory high-risk tumors.
Rebecca Gardner, MD
Director of Cellular Therapy Integration
Meaghan Granger, MD
Director of Oncology Clinical Medicine
From the Pediatric Cancer Genome Project and beyond, @stjuderesearch has a long history of genetic discovery. Read about the work of our scientists on the genetics of vulnerabilities, predisposition, molecular groups and data analysis. #StJudeOn
DNA isn't destiny, but genetic predispositions do underlie many cancers. St. Jude scientists have gained a nuanced understanding of cancer predisposition and are learning more to help personalize patient therapies. Learn more. #StJudeOn
Cancer is not a monolith but a landscape of diseases with different drivers. Scientists at St. Jude are leading studies on how understanding molecular groups can advance cancer care. Read about it. #StJudeOn
Studying genomics means creating big data. Scientists at St. Jude have developed numerous tools and techniques for tackling data with cutting-edge visualizations and analysis. Learn more. #StJudeOn
St. Jude is the first and only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children.
Discover career opportunities in Oncology at St. Jude
Department of Oncology
MS 260, Room C6056
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Telephone: (901) 595-4329
Fax: (901) 521-1751
Preferred contact method: email